Publicacións en colaboración con investigadores/as de Erasmus University Medical Center (52)

2024

  1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study

    American Journal of Preventive Cardiology, Vol. 17

  2. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993

  3. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1821-1831

  4. Linguistic and cultural properties of the Spanish adaptation of the CAT (SP-CAT): pilot results from neurotypical subjects

    Aphasiology

  5. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  6. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356

  7. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group

    Clinical Microbiology and Infection

  8. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

  9. Validation of the abbreviated version of the Token Test in Latin American Spanish stroke patients

    International Journal of Language and Communication Disorders

2023

  1. Fulminant myocarditis proven by early biopsy and outcomes

    European Heart Journal, Vol. 44, Núm. 48, pp. 5110-5124

  2. How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registry

    ESC Heart Failure, Vol. 10, Núm. 2, pp. 884-894

  3. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

    Annals of Oncology, Vol. 34, Núm. 5, pp. 468-476

  4. Sex-related differences in left ventricular assist device utilization and outcomes: results from the PCHF-VAD registry

    ESC Heart Failure, Vol. 10, Núm. 2, pp. 1054-1065

  5. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799

2022

  1. An aphasia research agenda–a consensus statement from the collaboration of aphasia trialists

    Aphasiology, Vol. 36, Núm. 4, pp. 555-574

  2. Extended anticoagulation for venous thromboembolism: A survey of the American Venous Forum and the European Venous Forum

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 10, Núm. 5, pp. 1012-1020.e3

  3. Impact of progressive aortic regurgitation on outcomes after left ventricular assist device implantation

    Heart and Vessels, Vol. 37, Núm. 12, pp. 1985-1994

  4. Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry

    European Journal of Heart Failure, Vol. 24, Núm. 7, pp. 1305-1315

  5. Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases

    The Journal of clinical endocrinology and metabolism, Vol. 107, Núm. 8, pp. e3313-e3320

  6. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1106-1114